Core A: University of Kentucky Alzheimer's Disease Core Center
Core A: University of Kentucky Alzheimer's Disease Core Center
批准号:
10459466
负责人:
LINDA J VAN ELDIK
金额:
$27.88万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-08-01 至 2026-06-30
关键词:
AdministratorAlzheimer&aposs DiseaseAlzheimer&aposs Disease Core CenterAlzheimer&aposs disease related dementiaAutopsyBiologicalBrainBrain PathologyCapitalCaregiversCessation of lifeClinicalCognitiveCognitive agingCollaborationsCommunicationCommunitiesDementiaDevelopmentDoctor of PhilosophyElderlyEnsureEnvironmentEtiologyFosteringFoundationsGoalsHeterogeneityHuman ResourcesHuman VolunteersImpaired cognitionIndividualInfrastructureKentuckyKnowledgeLeadershipModalityMonitorNeurosciencesOccupational activity of managing financesPathogenicityPathologyPatientsPreventionResearchResearch ActivityResearch PersonnelResourcesRiskRisk FactorsScienceStrategic PlanningStructureSystemTissuesTraining and EducationTranslational ResearchUnited StatesUniversitiesaccurate diagnosticsbeneficiarycognitive developmentcohortcomorbiditydiagnostic strategydisease heterogeneityeffective therapyinnovationmeetingsmultidisciplinarynovel therapeuticspre-clinicalpreventprogramssuccesstraining opportunitytreatment strategyvolunteer
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract: Administrative Core
The ultimate goal of the UK-ADRC is to catalyze innovative and outstanding AD research while ensuring a
more rapid rate of progress toward new therapies to delay or prevent AD, so that our human volunteers,
patients and caregivers become the beneficiaries of our advances in knowledge. The Administrative Core
provides the foundation, infrastructure, leadership, overall direction, strategic planning, and integration of all
ADRC components to more rapidly achieve this goal and advance our overall theme: “Transitions from Normal
to Late-Life Multi-Etiology Dementia”. This theme builds on our traditional strengths in defining mechanisms
underlying the early changes that occur in individuals as they transition through the cognitive continuum, risk
factors associated with these cognitive states, and how mixed pathology and co-morbidities influence risk and
progression. Two historically outstanding resources of the UK-ADRC that enable research relevant to this
theme are: 1) a strong autopsy program providing clinical-neuropathological correlation and very short (2-4 hrs)
postmortem interval (PMI) research material, and 2) a unique, continuously replenished group of ~500
cognitively intact subjects followed longitudinally, together with another ~300 initially normal individuals who
transition to pre-MCI, MCI or dementia, and all committed to brain autopsy upon death. These signature
resources have contributed to our becoming one of the premier centers defining pathogenic mechanisms
underlying the transitions from normal cognitive aging to the earliest stages of cognitive impairment. The UK-
ADRC functions in a multidisciplinary, integrated, collaborative and supportive team science environment that
catalyzes high-quality AD research within the UK community, region, nation, and beyond. We will continue to
provide the infrastructure, resources and intellectual capital to enhance transdisciplinary research and scientific
interactions, develop new collaborations and partnerships, contribute to national initiatives, and offer innovative
education and training opportunities in the basic and clinical neurosciences. An effective Administrative Core is
essential for transforming our goals into accomplishments. Therefore, the Core will continue to support the
ability of our UK-ADRC to accomplish its goals, and to promote the NAPA research implementation milestones
and goals, through the following specific aims.
Aim 1: Provide leadership, administrative structure, coordination, and financial management to ensure optimal
resource utilization to meet the overall goals of the UK-ADRC.
Aim 2: Promote and catalyze clinical/translational research activities, maximize interactions with other
departments and centers, and foster new avenues of innovative research.
Aim 3: Solicit, review, select, and monitor the Developmental Projects.
Aim 4: Contribute to and interact with other ADRCs and other national collaborative activities and increase
visibility in the local and national community.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
GMP Production and Extended Toxicology of an Oral Formulation Drug for Alzheimer's Disease
-
批准号:10624841
-
项目类别:
-
资助金额:$154.73万
-
财政年份:2022
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Portable and modular UDS Data Collection software to increase collaboration and engagement of Alzheimer’s Disease Research Center research software engineers
-
批准号:10608722
-
项目类别:
-
资助金额:$22.93万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Core A: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10261962
-
项目类别:
-
资助金额:$35.53万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
University of Kentucky Alzheimer's Disease Research Center
-
批准号:10662314
-
项目类别:
-
资助金额:$288.09万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Core G: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10662371
-
项目类别:
-
资助金额:$16.33万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Core A: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10662339
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Core G: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10459472
-
项目类别:
-
资助金额:$16.33万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
University of Kentucky Alzheimer's Disease Research Center
-
批准号:10459464
-
项目类别:
-
资助金额:$293.7万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
University of Kentucky Alzheimer's Disease Research Center
-
批准号:10261961
-
项目类别:
-
资助金额:$300.99万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Core G: University of Kentucky Alzheimer's Disease Core Center
-
批准号:10261968
-
项目类别:
-
资助金额:$12.01万
-
财政年份:2021
-
负责人:LINDA J VAN ELDIK
-
依托单位:
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation
-
批准号:10307828
-
项目类别:
-
资助金额:$33.66万
-
财政年份:2019
-
负责人:LINDA J VAN ELDIK
-
依托单位:
First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation
-
批准号:10061521
-
项目类别:
-
资助金额:$119.36万
-
财政年份:2019
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD
-
批准号:9272346
-
项目类别:
-
资助金额:$146.89万
-
财政年份:2015
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Microglia responses to CNS injury: targeting p38 MAPK signaling
-
批准号:8985734
-
项目类别:
-
资助金额:$32.9万
-
财政年份:2015
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Microglia responses to CNS injury: targeting p38 MAPK signaling
-
批准号:9265338
-
项目类别:
-
资助金额:$32.92万
-
财政年份:2015
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Microglia responses to CNS injury: targeting p38 MAPK signaling
-
批准号:9059183
-
项目类别:
-
资助金额:$32.92万
-
财政年份:2015
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD
-
批准号:9134677
-
项目类别:
-
资助金额:$140.34万
-
财政年份:2015
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Preclinical Development of a Selective Suppressor of Neuroinflammation for MCI/AD
-
批准号:8944142
-
项目类别:
-
资助金额:$141.63万
-
财政年份:2015
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Modulation of CNS Proinflammatory Cytokine Production
-
批准号:7888622
-
项目类别:
-
资助金额:$29.24万
-
财政年份:2010
-
负责人:LINDA J VAN ELDIK
-
依托单位:
Modulation of CNS Proinflammatory Cytokine Production
-
批准号:8269733
-
项目类别:
-
资助金额:$28.65万
-
财政年份:2010
-
负责人:LINDA J VAN ELDIK
-
依托单位: